Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android


certolizumab pegol (ser-toe-liz-u-mab peg-all)



Therapeutic: gastrointestinal anti-inflammatories—therapeutic

Pharmacologic: tumor necrosis factor blockers


Moderate-to-severe active Crohn's disease when response to conventional therapy has been inadequate.


Neutralizes tumor necrosis factor (TNF), a prime mediator of inflammation; pegylation provides a long duration of action. Therapeutic Effects: Decreased signs/symptoms of Crohn's disease.

Adverse Reactions/Side Effects

Derm: skin reactions (rarely severe). Hemat: hematologic reactions. MS: arthralgia. Misc: ALLERGIC REACTIONS, INCLUDING ANAPHYALXIS, INFECTIONS, lupus-like syndrome.


Examination and Evaluation

  • Monitor signs of allergic reactions and anaphylaxis, including pulmonary symptoms (tightness in the throat and chest, wheezing, cough, dyspnea) or skin reactions (rash, pruritus, urticaria). Notify physician or nursing staff immediately if these reactions occur.

  • Be alert for signs of systemic infections, especially respiratory infections (fever, chills, cough, mucus production, shortness of breath, wheezing, chest discomfort, fatigue) and GI infections (nausea, vomiting, diarrhea, abdominal pain). Notify physician immediately of these signs.

  • Monitor signs of hematologic reactions such as leukopenia (fever, sore throat, signs of infection), thrombocytopenia (bruising, nose bleeds, and bleeding gums), or unusual weakness and fatigue that might be due to anemia. Report any suspicious signs of blood disorders.

  • Monitor any changes in GI symptoms (decreased abdominal pain, decreased diarrhea, improved appetite) to help document whether drug therapy is successful in managing Crohn's disease.

  • Assess any joint pain to rule out musculoskeletal pathology; that is, try to determine if pain is drug induced rather than caused by anatomic or biomechanical problems.

  • Monitor signs of lupus-like syndrome, including increased blood pressure (BP), fever, joint pain, skin rashes, and redness/irritation of the eye (uveitis). Notify physician promptly if these signs appear.

Patient/Client-Related Instruction

  • Advise patient to avoid alcohol and foods that may cause an increase in GI irritation.

  • Instruct patient and family/caregivers to report other troublesome side effects such as severe or prolonged skin reactions (rash, dermatitis).


Absorption: 80% absorbed following SC administration.

Distribution: Unknown.

Metabolism and Excretion: Unknown.

Half-life: 14 days.

|Download (.pdf)|Print

TIME/ACTION PROFILE (blood levels)

SC unknown 50–120 hr 2–4 wk


Contraindicated in: Active untreated infection; Hepatitis B reactivation.

Use Cautiously in: History of recurrent infections, concurrent immunosuppressants, medical conditions associated with increased risk of infection, current residence in areas where tuberculosis or histoplasmosis are endemic, history of hepatitis B infection (may reactivate); History of demyelinating disorders (may exacerbate); History of heart failure; Geri: May increase risk of infections; OB: Use pregnancy only if clearly ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.